Insulin degludec is a new ultra-long-acting insulin analogue

Dedov, Ivan I.; Иванович, Дедов Иван; Shestakova, Marina Vladimirovna; Владимировна, Шестакова Марина

doi:10.14341/dm2014291-104

Cited by 5 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Во-первых, были созданы два аналога, продолжительность действия которых больше 24 ч. Но главная их особенность -это ровный профиль действия, что заметно снижает риск любых гипогликемий по сравнению с аналогами инсулина предыдущего поколения. Это инсулин деглудек («Ново Нордиск», 2013) с длительностью действия 42 ч и более [7] и инсулин гларгин 300 ЕД/мл («Санофи», 2017) с длительностью действия около 36 ч [8].…”

Section: следующее поколение аналогов инсулинаunclassified

On the centenary of the insulin discovery

Dedov

Shestakova

2021

Diabetes mellitus

View full text Add to dashboard Cite

The discovery of insulin and the beginning of its use in 1921–1922 made a revolution in endocrinology and in medicine in general. This significant event gave millions of patients with diabetes not only the opportunity to live, but also the hope that their life with this disease would be full.The article examines the history of insulin discovery, as well as the evolution of several generations of insulin preparations and the advantages of each of the generations that have radically changed not only life expectancy, but also its quality.The first generation — insulins of animal origin and the solution of the first tasks of their sufficient production and purification. The next generation is human insulins, the purification of which was also a problem. The third generation is insulin analogues, the action of which became closer to the action profile of natural insulin. And the last generation — insulin analogues, most closely mimicking the action of endogenous insulin.Along with the development of insulin preparations, the article traces the evolution of the devices of its administration.

show abstract

Section: следующее поколение аналогов инсулинаunclassified

On the centenary of the insulin discovery

Dedov

Shestakova

2021

Diabetes mellitus

View full text Add to dashboard Cite

show abstract

Pharmacoepidemiological analysis of type 1 diabetes mellitus insulin therapy (According to the Moscow segment of the State Register of Diabetes Mellitus)

Antsiferov,

Kantemirova,

Demidov

et al. 2023

Diabetes mellitus

View full text Add to dashboard Cite

BACKGROUND: When developing programs for state reimbursement of the cost of medical services and medicines, when providing assistance to patients suffering from type 1 diabetes mellitus (DM1), data based on the results of pharmacoepide-miological studies (FEI) conducted in real clinical practice of treating patients are needed. The obtained results of the analysis of drug consumption allow us to study the most commonly used insulin therapy regimens and their compliance with modern clinical recommendations. Calculations of the weighted average cost of conducting hypoglycemic therapy in DM1 can be used for further pharmacoeconomical calculations, including analysis of the medical and social cost of the disease.AIM: To conduct a pharmacoepidemiological analysis of the consumption of insulin preparations according to the ATX /DDD methodology, to study the modes of insulin administration and the ratio of the weighted average cost of insulin therapy components per 1 patient with DM1 per year in the outpatient practice of treatment with the introduction of insulin in the mode of multiple injections of insulin (MII) and during continuous subcutaneous insulin infusion (CSII).MATERIALS AND METHODS: A retrospective continuous cohort analytical pharmacoepidemiological study was conducted on the basis of the SRDM database (status as of 01/01/2020), in which 17,617 patients with T1DM aged 18 years and older were registered at the time of the study.RESULTS: 90% of patients received analogues of human insulin in the MII mode using syringe pens, 8.6% used the CSII mode. In 34.5% of patients with DM1 HbA1c was <7%, the proportion of patients with HbA1c >8% was 28%. The average cost of insulin therapy per 1 person per year was 54,977 rubles. The cost of basal insulin treatment per 1 patient per year was approximately 1.5 times higher than the cost of bolus insulin during insulin therapy in the MII mode (33,960 rubles and 21,017 rubles, respectively). The weighted average cost of insulin per 1 patient per year for CSII was 31,822 rubles.CONCLUSION: The majority of patients with DM1 in the study cohort received analogues of human insulin in the basic bolus mode of MII using syringe pens, which corresponds to existing clinical recommendations. The proportion of patients achieving the goals of glycemic control is comparable to the data obtained on the basis of registers of diabetic patients in other economically developed countries

show abstract

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice

et al. 2015

Self Cite

View full text Add to dashboard Cite

Цель. Оценить эффективность и безопасность лечения сахарного диабета 2 типа (СД2) с использованием нового препарата инсулина сверхдлительного действия деглудек (Тресиба®) в условиях повседневной клинической практики. Материалы и методы. В клиническом наблюдении, в условиях первичного медико-санитарного уровня, приняли участие 20 па-циентов СД2 (средний возраст -57,2 [54,4; 61,5] Federation (12.28.2012. Quality of life was assessed using the SF-36 questionnaire. All patients provided written consent before participating in the study.

show abstract

Insulin degludec is a new ultra-long-acting insulin analogue

Cited by 5 publications

References 51 publications

On the centenary of the insulin discovery

On the centenary of the insulin discovery

Pharmacoepidemiological analysis of type 1 diabetes mellitus insulin therapy (According to the Moscow segment of the State Register of Diabetes Mellitus)

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice

Contact Info

Product

Resources

About